



Identification of prognostic immune cells and potential immune-related markers in hepatocellular carcinoma

Jialuo Mai^{1#}, Xuefeng Hua^{1#}, Zhen-Hua Bian², Yu Xia¹, Zhi-Bin Zhao³, Minqiang Lu¹

¹Department of HBP Surgery II, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China; ²Chronic Disease Laboratory, Institutes for Life Sciences, South China University of Technology, Guangzhou, China; ³Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

Contributions: (I) Conception and design: J Mai, X Hua, M Lu; (II) Administrative support: ZB Zhao, X Hua; (III) Provision of study materials or patients: J Mai, ZH Bian; (IV) Collection and assembly of data: Y Xia, ZH Bian; (V) Data analysis and interpretation: J Mai, X Hua, M Lu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Minqiang Lu, MD, PhD. Department of HBP Surgery II, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong Province, China. Email: larrylmq@outlook.com.

Background: Hepatocellular carcinoma (HCC) is one of the most common and deadly tumors worldwide. Immunotherapy has emerged as a promising strategy for HCC treatment, and understanding the immune microenvironment of HCC provides a theoretical basis for identifying new immune targets. However, the roles of immune components and their regulatory mechanisms in HCC require further clarified.

Methods: By analyzing HCC expression profiles from The Cancer Genome Atlas (TCGA) database, we depicted the proportion profile of immune cells for each sample using the software CIBERSORTx. Using R packages, we also characterized the distribution of differentially expressed genes (DEGs) in immune cells, calculated the correlation coefficient between immune cells and common DEGs, and analyzed their biology function by Gene-Ontology analysis.

Results: We found that seven immune cell types were related to the overall survival of HCC patients, and identified 3,692 differentially expressed immune-related genes, predominantly functioning in nucleic acid processing and metabolism. Moreover, 14 DEGs were identified as common candidates related to immune cells and overall survival.

Conclusions: Our study not only presents an overview of the immune features of the microenvironment of HCC, but also provides potential targets related to immune components.

Keywords: Hepatocellular carcinoma (HCC); The Cancer Genome Atlas (TCGA); tumor microenvironment (TME); bioinformatic analysis

Submitted Jan 04, 2022. Accepted for publication May 09, 2022.

doi: 10.21037/tcr-22-19

View this article at: <https://dx.doi.org/10.21037/tcr-22-19>

Introduction

Primary liver cancer, one of the most common cancers, contributes to a large number of cancer-related deaths worldwide (1,2). Hepatocellular carcinoma (HCC) accounts for the majority of cases among all types of primary liver cancers (3). The main risk factors for HCC development include liver cirrhosis, infection with hepatitis B virus (HBV)/hepatitis C virus (HCV), alcohol abuse, and

metabolic syndrome (4-7). In addition, other factors, such as smoking and aflatoxin B1 intake, have been identified as contributors to HCC (8,9). HCC is frequently characterized by mutations in TERT, TP53, and ARID1A, and dysregulation of the WNT, RAS, and mTOR signaling pathways (10,11). However, not all of these onco-drivers are considered druggable targets, and pharmaceuticals for HCC treatment currently available pharmaceuticals

Table 1 Clinicopathologic parameters of HCC patients in TCGA cohorts

Clinicopathologic parameters	TCGA	
	Total (n=369)	%
Age, years		
<60	169	45.80%
≥60	199	53.93%
Not reported	1	0.27%
Gender		
Male	249	67.48%
Female	120	32.52%
T		
T1	181	49.05%
T2	94	25.47%
T3	78	21.14%
T4	13	3.52%
Tx	1	0.27%
Not reported	2	0.54%
N		
N0	250	67.75%
N1	4	1.08%
Nx	114	30.89%
Not reported	1	0.27%
M		
M0	265	71.82%
M1	4	1.08%
Mx	100	27.10%
Stage		
I	171	46.34%
II	86	23.31%
III	83	22.49%
IV	5	1.36%
Not reported	24	6.50%

HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas.

are currently limited. Tyrosine kinase inhibitors (TKIs) such as Sorafenib, Regorafenib, and Lenvatinib have been demonstrated to have limited survival advantages for HCC

(12-14). However, identification of novel druggable targets for more effective treatment of HCC has inevitably become a priority.

Recently, there has been an increase in research focusing on the tumor microenvironment (TME), in particular, its immune component. It is widely accepted that the immune components of the TME significantly influence the pathophysiological progress of tumors, therapeutic responses, and clinical outcomes (15-17). Furthermore, immunotherapies that modulate the immune response against tumors are making promising clinical progress. Antibodies blocking immune-checkpoint molecules, such as PD-1 and CTLA-4, are being tested and put into clinical application with inspiring results (18). Thus, a deeper understanding of the immune components of the TME is indispensable for developing novel strategies for HCC treatment.

To explore the role of immune components in HCC, we used TCGA database and screened immune cells that were related to overall survival in HCC patients. Next, we identified common genes that were related to candidate immune cells and found that 14 candidates were correlated with overall survival. To study the biological role of the differentially expressed genes (DEGs) related to immune components, we used gene ontology (GO) analysis to identify the enriched pathways and functions. Our study characterizes the immune features of HCC, and provides potential clues on HCC therapies. We present the following article in accordance with the REMARK reporting checklist (available at <https://tcrc.amegroups.com/article/view/10.21037/tcr-22-19/rc>).

Methods

Samples collection and data processing

Expression data with clinical information from HCC patients were downloaded from The Cancer Genome Atlas (TCGA) website (<https://portal.gdc.cancer.gov/>). These data included fifty files from normal tissues and 369 individual files from tumor tissues. The Fragments Per Kilobase per Million (FPKM) values were used in subsequent analyses. The clinicopathologic features of HCC patients were shown in *Table 1* and website: <https://cdn.amegroups.cn/static/public/tcr-22-19-01.zip>. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Since the data from the TCGA were de-identified and publicly available, no institutional review board approval was necessary and no informed consent was signed for this study.

Identifying immune cells related to survival

We calculated the proportions of 22 types of immune cells using software CIBERSORTx. First, we uploaded the matrix of FPKM values for all samples to the CIBERSORTx website (<https://cibersortx.stanford.edu/index.php>) as the Mixture file. Next, we selected the LM22 matrix (default setting) within the software as the signature gene file, and ran the software in the relative mode, with batch correction and quantile normalization both disabled. We set the permutations for significance analysis to 100. We then identified survival-related immune cells using the survival R package based on the proportion of each cell type. We used the log-rank test to analyze the survival data and set the medians of the proportions of cell types as the cut-off values. We analyzed the relationship between the proportions of immune cells and clinical stages using the one-way ANOVA.

Identification of immune-related genes and common genes

The specific genes for each type of survival-related immune cell were identified by calculating the DEGs between the high- and low-expressing samples using the median of proportions as the cut-off value. DEGs were analyzed using the limma R package. Benjamini & Hochberg (BH) method for multiple hypothesis testing on the P values were performed in differential expression analysis. Significantly altered genes for each cell type included those with $|\log_2(\text{FoldChange (FC)})| > 2$, and P value < 0.05 . The results were visualized using the ggplot2 R package. Common genes were screened and visualized by UpSet R package.

Enrichment analysis of immune-related genes and common genes

Significant Gene Ontology (GO) enrichment analyses were performed using the cluster profiler R package. A P value < 0.05 , and $|\text{ave_log2FC}| > 2$, were chosen as the thresholds.

Relationship between immune components and common genes

We calculated the Pearson correlation between the common genes and 22 types of immune components, and the result was visualized by the ggplot2 R package. Additionally, we calculated the correlation between the common genes and the overall survival by the Log-Rank test.

Statistical analysis

Method of one-way analysis of variance (ANOVA) was performed to compare differences in immune cell components among stages, while Tukey's multiple comparisons test was performed to compare differences in components of immune cells between any two of stages.

Results

Identifying immune cells related to HCC overall survival

It is widely reported that immune infiltration is related to the occurrence, progression, and prognosis of HCC. To further explore the relationship between immune components and prognosis in HCC, the proportions of 22 types of immune cells were calculated using the online software CIBERSORTx (Figure 1A) (19). The proportion of macrophages was $39.9\% \pm 11.8\%$ and T cells was $36.28\% \pm 12.8\%$, which accounted for the majority of immune cells (Figure 1B).

By analyzing the survival data of HCC patients in TCGA cohorts, we identified the proportion of M0 macrophages (OS: HR = 0.4688, 95% CI: 0.3284 to 0.6692, logrank $P < 0.0001$), naïve B cells (OS: HR = 1.579, 95% CI: 1.107 to 2.254, logrank $P = 0.011$), resting mast cells (OS: HR = 1.577, 95% CI: 1.109 to 2.242, logrank $P = 0.011$), CD4⁺ T cells (memory resting) (OS: HR = 1.494, 95% CI: 1.055 to 2.116, logrank $P = 0.023$), follicular helper T (T_{fh}) cells (OS: HR = 0.6425, 95% CI: 0.4536 to 0.9101, logrank $P = 0.012$), $\gamma\delta$ T cells (OS: HR = 1.648, 95% CI: 1.146 to 2.369, logrank $P = 0.0064$), and eosinophils (OS: HR = 0.5744, 95% CI: 0.3284 to 1.005, logrank $P = 0.049$) as candidate immune cells related to overall survival (Figure 1C). Higher proportions of T_{fh} cells, M0 macrophages and eosinophils correlated with worse prognosis, while higher proportions of naïve B cells, CD4⁺ T cells (memory resting), $\gamma\delta$ T cells, and resting mast cells correlated with better prognosis (Figure 1D). Thus, we considered these six types of immune cells as survival-related cells, and as immune candidates for further investigation.

Exploring the relationship between immune cells and clinical stages of HCC

Next, we investigated the relationship between the proportions of each type of immune cells at different clinical stages. The proportions of memory resting CD4⁺ T cells were statistically different in distinct clinical stages




Figure 1 The relationship between the proportion of immune cells and overall survival in HCC. (A) The profile of the proportion of immune cells in the HCC samples. Each sample is represented by one column, and the proportion of the specific immune cell types is indicated by the column height in that sample. (B) The proportion of 22 types of immune cells in the HCC samples. Medians and quartiles are shown in black lines. (C,D) Survival analysis for the proportion of (C) follicular helper T (T_{fh}) cells, M0 macrophages, eosinophils, (D) naïve B cells, resting memory CD4⁺ T cells, $\gamma\delta$ T cells, and resting mast cells. HCC, hepatocellular carcinoma.

($P < 0.05$), while the proportion of M0 macrophages was significantly lower in stage I than in stages II ($P < 0.05$) and III ($P < 0.05$), and the proportion of M1 macrophages was significantly higher in stage I than in stage III ($P = 0.0431$). However, the proportions of most types of immune cells showed no statistical difference in the distinct clinical stages of HCC (Figure 2). These results suggest that there is no clear relationship between the proportion of immune cells, including survival-related immune cells, and clinical stages.

Identification of DEGs related to immune cells and pathway analysis

Gene expression relating to the specific immune cell candidates was assessed as described in the 'Methods' section, revealing a total of 3,692 DEGs. Among these genes, 1,531 were related to naïve B cells, 2,321 to M0 macrophages, 1,277 to Tfh cells, 1,447 to memory resting CD4⁺ T cells, 797 to $\gamma\delta$ T cells, 1,683 to resting mast cells, and 1,283 to eosinophils (Figure 3A-3G).

Next, to explore the biological function of the DEGs, we performed Gene Ontology (GO) pathway enrichment analysis for each group of immune-related DEGs. The results of top 30 pathways are shown in Figure 3H,3I. The DEGs were mainly enriched in the regulation of RNA-related processes (like metabolism and splicing), immune responses (like T cell activation, neutrophils activation, and immune-related cell surface receptor signal pathway), and mitosis-related processes (Figure 3H,3I and website: <https://cdn.amegroups.cn/static/public/tcr-22-19-01.zip>). The results of the GO pathway enrichment analysis therefore suggest that RNA-related signal pathway may play a pivotal role in regulating immune components of HCC.

Identification and analysis of common genes related to immune cells

We identified the distribution of DEGs in the overall survival-related immune cells to explore the common genes which may play important roles in regulating immune cells (Figure 4A). Sixteen genes were differentially expressed in all seven types of immune cells, including *MFSD10*, *DBN1*, *ALDOA*, *ELOVL1*, *CBX3*, *HLF*, *HMGA1*, *TPD52L2*, *WDR1*, *SLC25A6*, *SYNGR2*, *ENO1*, *G6PD*, *COLGALT1*, *MANBAL*, and *JPT2*. The expression pattern of 16 genes is shown in Figure 4B, and it was shown that the expression pattern of *HLF* seemed to be negatively correlated to the other 15 genes. Thus, 16 genes were considered as

candidate genes of immune cells in HCC.

Exploring the relationship between common genes and clinical features of HCC

Relationship between overall survival and 16 candidates were explored, and 14 out of 16 genes (*ALDOA*, *CBX3*, *COLGALT1*, *ELOVL1*, *ENO1*, *G6PD*, *HLF*, *HMGA1*, *JPT2*, *MANBAL*, *MFSD10*, *SLC25A6*, *SYNGR2*, and *TPD52L2*) were shown to be correlated to overall survival significantly (Figure 5). Higher expression of *ALDOA* (OS: HR = 0.5686, 95% CI: 0.4008 to 0.8066, logrank $P = 0.0013$), *CBX3* (OS: HR = 0.5425, 95% CI: 0.3811 to 0.7723, logrank $P = 0.00057$), *COLGALT1* (OS: HR = 0.6135, 95% CI: 0.4323 to 0.8706, logrank $P = 0.0057$), *ELOVL1* (OS: HR = 0.5433, 95% CI: 0.3827 to 0.7715, logrank $P = 0.00054$), *ENO1* (OS: HR = 0.4941, 95% CI: 0.3465 to 0.7047, logrank $P < 0.0001$), *G6PD* (OS: HR = 0.5214, 95% CI: 0.3672 to 0.7404, logrank $P = 0.00021$), *HMGA1* (OS: HR = 0.5283, 95% CI: 0.3717 to 0.7509, logrank $P = 0.0003$), *JPT2* (OS: HR = 0.6893, 95% CI: 0.4878 to 0.9739, logrank $P = 0.034$), *MANBAL* (OS: HR = 0.6095, 95% CI: 0.4304 to 0.8630, logrank $P = 0.0048$), *MFSD10* (OS: HR = 0.6126, 95% CI: 0.4325 to 0.8676, logrank $P = 0.0053$), *SLC25A6* (OS: HR = 0.7061, 95% CI: 0.4984 to 1.000, logrank $P = 0.049$), *SYNGR2* (OS: HR = 0.5931, 95% CI: 0.4173 to 0.8428, logrank $P = 0.0032$), and *TPD52L2* (OS: HR = 0.5947, 95% CI: 0.4193 to 0.8435, logrank $P = 0.0032$) correlated with worse prognosis, while higher expression of *HLF* (OS: HR = 1.428, 95% CI: 1.007 to 2.025, logrank $P = 0.045$) correlated with better prognosis.

Also, the relationship between prognostic candidates and clinical stages were explored. We found that the expression levels of *ALDOA* and *MFSD10* increased with the increase of clinical stages. Meanwhile, the levels of *HLF* decreased with the increase of clinical stages. Also, the level of *CBX3*, *COLGALT1*, *JPT2*, *MANBAL*, *SYNGR2*, and *TPD52L2* increased with clinical stage I to III. The levels of *SLC25A6* increased in stage IV compared to stage I. The level of *ELOVL1*, *ENO1*, *G6PD*, and *HMGA1* showed no difference in distinct clinical stages (Figure 6).

Exploring the relationship between candidate genes and immune cells

Additionally, we explored the correlation between candidate genes and the proportions of 22 types of immune cells, and found that candidate genes were mainly correlated to the proportions of naïve B cells, Tregs, $\gamma\delta$ T cells, resting NK




Figure 2 The relationship between immune cells and HCC stages. The proportions of 22 types of immune cells in different clinical stages of HCC are shown in violin plots. Medians are shown in black lines. Quartiles are shown in dotted lines. *, $P<0.05$; **, $P<0.01$; ***, $P<0.001$. HCC, hepatocellular carcinoma.





Figure 3 Identification of DEGs related to immune cells and GO pathway analysis. (A-G) Gene expression profiles related to naive B cells, M0 macrophages, Tfh cells, memory resting CD4⁺ T cells, $\gamma\delta$ T cells, and resting mast cells. Volcano plots are used to present the data. The upregulated/downregulated genes are presented as red/blue dots according to the criteria: $|\log_2\text{Fold Change}| > 2$ and P value < 0.05 . (H-I) GO pathway enrichment analysis on genes related to each type of immune cells. The significance of enrichment results is indicated by the color, and the count of genes enriched for each result is indicated by the dot size. DEGs, differentially expressed genes; GO, Gene Ontology.



Discussion

Since the molecular and immune features of HCC have been comprehensively characterized (20,21), the prognostic value of immune-based markers has emerged. In this study, we aimed to identify the prognostic markers basing on key immune components of HCC. The key immune components of HCC were analyzed by calculating the proportions of 22 types of immune cells and the relationship




Figure 5 The relationship between common genes and overall survival. The survival analysis for the common gene *ALDOA*, *CBX3*, *COLGALT1*, *ELOVL1*, *ENO1*, *G6PD*, *HLF*, *HMGA1*, *JPT2*, *MANBAL*, *MFSD10*, *SLC25A6*, *SYNGR2*, and *TPD52L2*.

with overall survival of HCC patients. The results showed a diversification of the proportions of immune cells among patients, indicating an important role and the complexity of the immune component of HCC.

In our study, seven types of immune cells were found to be related to HCC survival, including naïve B cells, Tfh, CD4⁺ T Cells (memory resting), $\gamma\delta$ T cells, M0 macrophages, eosinophils, and resting mast cells. An increasing number of studies have identified specific immune cells as prognostic markers in HCC, including

B cells, T cells, macrophages, and mast cells. Zhang *et al.* analyzed the distribution of B cells in HCC patients by multiplexed IHC and cytometry, and found that a high density of naïve B cells was a potential prognosticator for survival (22). Dysfunction of circulating Tfh cells has been reported to lead to HCC progression, and Tfh cells have potential as prognostic markers and a novel therapeutic targets (23,24). These findings, which were based on circulating Tfh, contradict with our results that a higher proportion of Tfh cells were associated with worse




Figure 6 The relationship between common genes and HCC traits. The expression level of common genes in different clinical stages of HCC were shown in box plots. Medians and quartiles were shown in black lines. HCC, hepatocellular carcinoma.

prognosis, therefore the role of infiltrating Tfh cells needs further investigation. These results suggest that these seven types of immune cells could be predictors and potential targets of HCC prognosis.

We also analyzed the DEGs related to immune cells and their biological functions, and found that DEGs were mostly enriched in RNA-related processes (like RNA splicing and RNA metabolism), immune responses (like T cell activation, neutrophils activation, and regulation of immune-related cell surface receptor signal pathway), and mitosis processes. It is implied that multiple processes especially RNA-related processes may play important

roles in immune microenvironment of HCC, and deserve to explore their therapeutic potential. For instance, it has widely reported that RNA N6-methyladenosine, which is a modification pattern of mRNA and involves in mRNA stability splicing and translation, plays a crucial part in HCC carcinogenesis and drug resistance (25,26).

Additionally, 16 common genes were identified from immune-related DEGs, and 14 of them (*ALDOA*, *CBX3*, *COLGALT1*, *ELOVL1*, *ENO1*, *G6PD*, *HLF*, *HMGA1*, *JPT2*, *MANBAL*, *MFSD10*, *SLC25A6*, *SYNGR2*, and *TPD52L2*) are significantly correlated with overall survival of HCC patients. HMGA1, a nuclear protein associated with




Figure 7 The relationship between common gene and immune components. The heatmap represents the Pearson correlation coefficients between common genes and immune components. *, $P < 0.05$.

chromatin remodeling, is overexpressed in multiple cancers, including thyroid cancer, liver cancer, and pancreatic cancer (27-29). Wei *et al.* reported that HMGA1, activated by PD-L1, promoted colorectal cancer stem cells expansion (30). In addition, several studies have suggested that *ALDOA*, *ENO1*, *HLF*, and *G6PD* are associated with cancer progression and immune response (31-34). It is generally accepted that macrophages are the main component in microenvironment of HCC, and play important roles in promoting or inhibiting hepatocarcinogenesis under particular circumstances (35). Interestingly, the proportions of M0 macrophages were significantly correlated to 16 candidate genes, indicating that M0 macrophage are associated with multiple biological aspects including energy metabolism, chromatin processing and RNA processing, and their potential relationships deserve further investigations. These results suggest that candidate genes may play a significant role in regulating immune components of HCC, and deserve further exploration the underlying mechanisms.

Our study has several limitations. First, the proportions of immune cells were calculated based on the TCGA dataset, so further validation will be required using other resources. Second, the relationship between immune

cells and prognostic candidates were calculated using mathematical methods. These results should be confirmed by molecular biology experiments such as RNA-interfering and proliferation assay. Third, the proportions of Tfh cells and $\gamma\delta$ T cells were zero in many cases, suggesting that the results relating to these two immune cell-types may rely on outliers. Therefore, conclusions regarding Tfh cells and $\gamma\delta$ T cells should be made with caution. Fourth, by the reason of limited information of viral load, the relationship between hepatitis virus infection and immune markers or common candidates were not explored further in our study.

In summary, we identified seven types of survival-related immune cell candidates and 16 common DEGs, and 14 of which were correlated with overall survival in HCC patients. These cells and candidate genes could be considered as prognostic markers, or potential targets for HCC treatment. Our research not only provides insights into immune cells of HCC, but also identifies potential therapeutic targets worth further exploration.

Conclusions

Our study not only presents an overview of the immune

features of the microenvironment of HCC, but also provides potential targets related to immune components.

Acknowledgments

Funding: This study was funded by the Science Foundation of Guangzhou First People's Hospital (No. Q2019010), the Program for Guangdong Introducing Innovative and Entrepreneurial Teams (No. 2017ZT07S054), and Guangdong Basic and Applied Basic Research Foundation (No. 2020A1515010897).

Footnote

Reporting Checklist: The authors have completed the REMARK reporting checklist. Available at <https://tcr.amegroups.com/article/view/10.21037/tcr-22-19/rc>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://tcr.amegroups.com/article/view/10.21037/tcr-22-19/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Since the data from the TCGA were de-identified and publicly available, no institutional review board approval was necessary and no informed consent was signed for this study.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018.
2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
3. Villanueva A. Hepatocellular Carcinoma. N Engl J Med 2019;380:1450-62.
4. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
5. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004;127:S87-96.
6. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-42.
7. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
8. Omer RE, Kuijsten A, Kadaru AM, et al. Population-attributable risk of dietary aflatoxins and hepatitis B virus infection with respect to hepatocellular carcinoma. Nutr Cancer 2004;48:15-21.
9. Marrero JA, Fontana RJ, Fu S, et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005;42:218-24.
10. Torrecilla S, Sia D, Harrington AN, et al. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. J Hepatol 2017;67:1222-31.
11. Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol 2016;65:1031-42.
12. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
13. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
14. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
16. Wu T, Dai Y. Tumor microenvironment and therapeutic

- response. *Cancer Lett* 2017;387:61-8.
17. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. *Nat Rev Immunol* 2017;17:559-72.
 18. Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. *Cancer Lett* 2020;470:8-17.
 19. Newman AM, Steen CB, Liu CL, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. *Nat Biotechnol* 2019;37:773-82.
 20. Guichard C, Amadio G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. *Nat Genet* 2012;44:694-8.
 21. Yarchoan M, Xing D, Luan L, et al. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. *Clin Cancer Res* 2017;23:7333-9.
 22. Zhang Z, Ma L, Goswami S, et al. Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma. *Oncoimmunology* 2019;8:e1571388.
 23. Zhou ZQ, Tong DN, Guan J, et al. Follicular helper T cell exhaustion induced by PD-L1 expression in hepatocellular carcinoma results in impaired cytokine expression and B cell help, and is associated with advanced tumor stages. *Am J Transl Res* 2016;8:2926-36.
 24. Jia Y, Zeng Z, Li Y, et al. Impaired function of CD4+ T follicular helper (Tfh) cells associated with hepatocellular carcinoma progression. *PLoS One* 2015;10:e0117458.
 25. Chen M, Wei L, Law CT, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. *Hepatology* 2018;67:2254-70.
 26. Lin Z, Niu Y, Wan A, et al. RNA m(6) A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. *EMBO J* 2020;39:e103181.
 27. Czyz W, Balcerczak E, Jakubiak M, et al. HMGI(Y) gene expression as a potential marker of thyroid follicular carcinoma. *Langenbecks Arch Surg* 2004;389:193-7.
 28. Chang ZG, Yang LY, Wang W, et al. Determination of high mobility group A1 (HMGA1) expression in hepatocellular carcinoma: a potential prognostic marker. *Dig Dis Sci* 2005;50:1764-70.
 29. Hristov AC, Cope L, Di Cello F, et al. HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. *Mod Pathol* 2010;23:98-104.
 30. Wei F, Zhang T, Deng SC, et al. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways. *Cancer Lett* 2019;450:1-13.
 31. Ji S, Zhang B, Liu J, et al. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. *Cancer Lett* 2016;374:127-35.
 32. Xu W, Yang W, Wu C, et al. Enolase 1 Correlated With Cancer Progression and Immune-Infiltrating in Multiple Cancer Types: A Pan-Cancer Analysis. *Front Oncol* 2021;10:593706.
 33. Xiang DM, Sun W, Ning BF, et al. The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis. *Gut* 2018;67:1704-15.
 34. Lu G, Shi W, Zhang Y. Prognostic Implications and Immune Infiltration Analysis of ALDOA in Lung Adenocarcinoma. *Front Genet* 2021;12:721021.
 35. Tian Z, Hou X, Liu W, et al. Macrophages and hepatocellular carcinoma. *Cell Biosci* 2019;9:79.

Cite this article as: Mai J, Hua X, Bian ZH, Xia Y, Zhao ZB, Lu M. Identification of prognostic immune cells and potential immune-related markers in hepatocellular carcinoma. *Transl Cancer Res* 2022;11(7):2262-2274. doi: 10.21037/tcr-22-19